alexa From Pigs to Patients: Transmissible, Single Gene-mediated Resistance to Colistin | Open Access Journals
ISSN: 2161-0703
Journal of Medical Microbiology & Diagnosis
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

From Pigs to Patients: Transmissible, Single Gene-mediated Resistance to Colistin

Joseph B McPhee1 and Shawn Lewenza2*

1Department of Chemistry and Biology, Ryerson University, Toronto, Ontario, Canada

2Faculty of Science and Technology, Athabasca University, Athabasca, Alberta, Canada

*Corresponding Author:
Shawn Lewenza
Faculty of Science and Technology
Athabasca University, Athabasca
Alberta, Canada
Tel: 17806752438
E-mail: [email protected]

Received: December30, 2015 Accepted:February 23, 2016 Published:February 26, 2016

Citation:McPhee JB, Lewenza S (2016) From Pigs to Patients: Transmissible, Single Gene-mediated Resistance to Colistin. J Med Microb Diagn 5:221. doi: 10.4172/2161-0703.1000221

Copyright: © 2016 McPhee JB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Medical Microbiology & Diagnosis

Commentary

The last decade has seen a stark increase in the number of multidrug resistant Gram-negative bacterial pathogens. Of particular importance are highly carbapenem resistant Escherichia coli and Klebsiella pneumoniae , as well as fluoroquinolone resistant Pseudomonas aeruginosa and Acinetobacter baumanii [1]. Owing to the lack of new drugs entering the marketplace, physicians are increasingly revisiting older drugs that had fallen out of common use. One such drug is colistin and it has increasingly become the drug of last resort for these infections [2]. Colistin is a polymyxin type of antimicrobial lipopeptide that is produced by Paenobacillus species. The polymxyins were discovered 65 years ago but have limited clinical use due to their neurotoxic and nephrotoxic side effects. Despite this toxicity in humans, colistin is used extensively in agriculture as growth promoters and estimates of global colistin usage in agriculture is >12,000 tonnes per annum. A recent report in the Lancet Infectious Diseases describes the first example of a transmissible plasmid that encodes colistin resistance by the mcr-1 gene. Colistin resistance was first detected in Escherichia coli isolates from pigs, but was ultimately found in meats for sale, and later in Chinese patients [3].

Clinical resistance to colistin is largely mediated through the modification of lipopolysaccharide via the addition of ethanolamine or 4-amino-arabinose to free phosphate moieties on the lipid A moiety. These additions reduce the negative charge and limit antimicrobial peptide binding and membrane disruption [4,5]. The emergence of clinical resistance to colistin is due to point mutations in regulatory proteins that control the genes responsible for these additions, PhoPQ and/or PmrAB (and MgrB in K. pneumoniae ) and were transmitted only vertically [6-9]. These data suggest that contrary to a common argument put forward by those developing novel antimicrobial peptides, resistance to this antibiotic class is common and now transmissable as single gene determinants.

The mcr-1 gene encodes a phosphoethanolamine transferase that adds a phosphoethanolamine to the phosphate groups of hexa-acylated lipid A, thereby blocking the negatively charged phosphates on lipid A, which otherwise serve as the binding site of cationic antimicrobial peptides [3,5]. The plasmid encoding mcr-1 is highly transmissible by conjugation to other E. coli isolates, and by transformation to other Gram-negative pathogens, resulting in 8-16 fold increases in colistin resistance [3]. In addition, the mcr-1 gene was active in an animal model of infection, demonstrating that it can provide a survival advantage during colistin -mediated chemotherapy [3]. This is the first description of plasmid-mediated colistin resistance and it represents a very important and worrisome development in infectious disease control.

In subsequent reports, the mcr-1 gene was found in food isolates of Salmonella enterica from Portugal and France [10,11], in six healthy individuals in Laos, Algeria and Thailand [12], in the gut micro biomes of healthy and diabetic Chinese subjects [13] and in E. coli samples from a prospective study of Dutch patients travelling to Southeast Asia [14]. Unpublished reports have also identified the mcr-1 gene in S. enterica and E. coli isolates in England and Wales, including at least 2 isolates from patients [15]. Perhaps most worrisome, the mcr-1 gene was found in an E. coli blood-borne infection isolate from a Danish patient with recurrent UTIs [15]. While the original report demonstrated that the mcr-1 gene was found on an IncI2 type plasmid, these short reports found the gene on IncX4 type plasmids as well showing that the gene is present in more than one plasmid type. While this is a very worrying observation, the mcr-1 gene has not yet been linked to any documented evidence of clinical colistin failure in humans.

In the Liu paper, the authors used a murine thigh model to demonstrate the effect of mcr-1 on in vivo colistin sensitivity [3]. Of interest, this experiment shows that in the absence of colistin , the mcr-1+ strain has a slight fitness defect [3]. Whether this is due to the mcr-1 gene itself or other genetic elements on pHNSHP45 is unknown, but it has been well documented that regulatory changes associated with colistin resistance often reduce the fitness of the organism containing those mutations in the absence of selection [6,7,16,17]. This suggests that removing the use of colistin may have the added benefit of selecting against the long-term survival of resistant isolates because of their reduced fitness relative to sensitive strains.

In summary, the observation of plasmid-mediated colistin resistance offers yet more evidence that antibiotic usage in agriculture needs to be drastically curtailed if we want to continue to use antibiotics to treat people. China is one of the largest users of colistin in agriculture, although use is widespread in the EU as well. Surveillance data in China has already demonstrated that colistin resistance is widespread in animal isolates. As there is limited development of new antimicrobials, particularly those directed toward Gram-negative pathogens, we ignore this development at our peril. Although this is the first example of plasmid-mediated colistin resistance, it is not likely the last, as there are other single candidate genes that could also lead to colistin resistance. There have been previous studies describing resistance to “last resort” antibiotics, and hopefully this example of colistin resistance will not lead to the “apocalypse pig” [18].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8003
  • [From(publication date):
    March-2016 - Jul 25, 2017]
  • Breakdown by view type
  • HTML page views : 7939
  • PDF downloads :64

Review summary

  1. Alexandra
    Posted on Oct 17 2016 at 5:23 pm
    This manuscript will be very important for our clinical, scientific, public-health and general readership. This study is clearly presented.
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords